Patients are walking into clinics asking for peptides they heard about on Joe Rogan, Huberman, and TikTok, and they trust those sources more than their doctor. Vikas Patel, an emergency medicine physician who also runs a longevity practice, breaks down what the evidence on BPC-157 actually shows, why the trust gap with statins and standard therapy exploded after COVID-19, and how absolutist physicians are losing patients to the Wild West of compounding pharmacies.

⏱️ Chapters:
0:00 Introduction
1:04 Why patients distrust statins but ask for peptides
2:24 Where your patients are actually hearing this
3:16 What peptides really are, and why most need injection
5:18 The BPC-157 story big pharma buried
7:14 14 patients studied, thousands using it
8:36 The statin evidence patients refuse to believe
9:41 What physicians got wrong communicating the data
12:06 What changed after COVID-19
12:38 How to handle the peptide request without losing trust
13:49 The cancer risk patients should know about
14:38 What a real course actually costs
16:04 The other longevity trends patients keep asking about
18:31 A message to physicians who say no to everything
20:54 Take home messages

About this episode:
Vikas Patel is an emergency medicine physician and former Navy flight surgeon who now runs a longevity practice, which puts him in front of patients asking weekly about peptides they heard about on podcasts and social media. He explains that BPC-157, the most-hyped tissue-repair peptide, was first studied in rodents in 1992, got bought by a biotech firm that never moved it through phase one trials, and to date has been documented in fewer than 20 patients in published trials, despite thousands using it. He contrasts this with the statin evidence base of millions of patients and explains why physicians fumbled the long-horizon argument for cholesterol management, looking at five and ten year data when the real benefit shows up over 40 years. Patel argues the trust collapse after COVID-19 means absolutist physicians who refuse to discuss non-evidence-based therapies are pushing patients straight to compounding pharmacies and TikTok. He walks through his own approach: present the data, name the unknowns, share the mechanistic concerns (like BPC-157's angiogenesis and theoretical cancer risk), and let the patient decide. He closes with a call for physicians to get educated on what patients are reading, and for patients to bring those questions to their doctor instead of the internet.

Tune into our episode "2026 Cholesterol Guidelines: LDL goals, lipoprotein(a), and coronary calcium scoring," brought to you by Novartis Pharmaceuticals Corporation.

For the first time in eight years, LDL cholesterol goals have changed, and preventive cardiologist Seth Baum says the new guidelines are a long-overdue course correction. He breaks down the new LDL targets for your highest-risk patients, why the LDL hypothesis should be retired in favor of the LDL fact, why lipoprotein(a) screening finally belongs in every patient's workup, what a coronary calcium score over 300 really means for how aggressively you treat, and how to talk to statin-skeptical patients without losing their trust. Listen now at KevinMD.com/cholesterol.

VISIT SPONSOR → https://kevinmd.com/cholesterol

🤝 Partner with me on the KevinMD platform:
With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Let's work together to tell your story.

➡️ PARTNER WITH KEVINMD: https://kevinmd.com/influencer
➡️ SUBSCRIBE TO THE PODCAST: https://www.kevinmd.com/podcast
➡️ RECOMMENDED BY KEVINMD: https://www.kevinmd.com/recommended

#PeptideTherapy #LongevityMedicine #PhysicianPatientTrust